A950130 Stock Overview
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
Access Bio Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩16,800.00|
|52 Week High||₩37,350.00|
|52 Week Low||₩14,350.00|
|1 Month Change||10.53%|
|3 Month Change||1.21%|
|1 Year Change||-24.32%|
|3 Year Change||362.81%|
|5 Year Change||253.68%|
|Change since IPO||62.32%|
Recent News & Updates
|A950130||KR Medical Equipment||KR Market|
Return vs Industry: A950130 underperformed the KR Medical Equipment industry which returned -4.7% over the past year.
Return vs Market: A950130 underperformed the KR Market which returned -14.3% over the past year.
|A950130 Average Weekly Movement||6.6%|
|Medical Equipment Industry Average Movement||5.6%|
|Market Average Movement||5.4%|
|10% most volatile stocks in KR Market||10.2%|
|10% least volatile stocks in KR Market||3.1%|
Stable Share Price: A950130 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: A950130's weekly volatility (7%) has been stable over the past year.
About the Company
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company was founded in 2002 and is headquartered in Somerset, New Jersey.
Access Bio Fundamentals Summary
|A950130 fundamental statistics|
Is A950130 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A950130 income statement (TTM)|
|Cost of Revenue||₩246.42b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||9.89k|
|Net Profit Margin||32.25%|
How did A950130 perform over the long term?See historical performance and comparison
Is Access Bio undervalued compared to its fair value and its price relative to the market?
Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: A950130 (₩16800) is trading below our estimate of fair value (₩4381422.81)
Significantly Below Fair Value: A950130 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: A950130 is good value based on its Price-To-Earnings Ratio (1.7x) compared to the KR Medical Equipment industry average (13.6x).
PE vs Market: A950130 is good value based on its Price-To-Earnings Ratio (1.7x) compared to the KR market (14.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A950130's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A950130 is good value based on its Price-To-Book Ratio (1x) compared to the KR Medical Equipment industry average (2.4x).
How is Access Bio forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Access Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Access Bio performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A950130 has high quality earnings.
Growing Profit Margin: A950130's current net profit margins (32.2%) are lower than last year (50.8%).
Past Earnings Growth Analysis
Earnings Trend: A950130 has become profitable over the past 5 years, growing earnings by 82.3% per year.
Accelerating Growth: A950130's earnings growth over the past year (104.5%) exceeds its 5-year average (82.3% per year).
Earnings vs Industry: A950130 earnings growth over the past year (104.5%) exceeded the Medical Equipment industry 15.1%.
Return on Equity
High ROE: A950130's Return on Equity (61.1%) is considered outstanding.
How is Access Bio's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A950130's short term assets (₩921.9B) exceed its short term liabilities (₩448.2B).
Long Term Liabilities: A950130's short term assets (₩921.9B) exceed its long term liabilities (₩41.7B).
Debt to Equity History and Analysis
Debt Level: A950130 has more cash than its total debt.
Reducing Debt: A950130's debt to equity ratio has reduced from 47.2% to 10% over the past 5 years.
Debt Coverage: A950130's debt is well covered by operating cash flow (1215.7%).
Interest Coverage: A950130's interest payments on its debt are well covered by EBIT (132.9x coverage).
What is Access Bio current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A950130's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A950130's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A950130's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A950130's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A950130 has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Young-Ho Choi (57 yo)
Mr. Young-Ho Choi serves as Chief Executive Officer and President of Access Bio, Inc. Mr. Choi has R&D and managements experience for IVD field. Mr. Choi is an Oak Ridge Conference Outstanding Awardee for...
CEO Compensation Analysis
Compensation vs Market: Young-Ho's total compensation ($USD995.23K) is about average for companies of similar size in the KR market ($USD913.39K).
Compensation vs Earnings: Insufficient data to compare Young-Ho's compensation with company performance.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Access Bio, Inc.'s employee growth, exchange listings and data sources
- Name: Access Bio, Inc.
- Ticker: A950130
- Exchange: KOSDAQ
- Founded: 2002
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: ₩594.563b
- Shares outstanding: 35.39m
- Website: https://www.accessbiodiagnostics.net
Number of Employees
- Access Bio, Inc.
- 65 Clyde Road
- Suite A
- New Jersey
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.